Literature DB >> 34134006

Combination of albumin-globulin score and skeletal muscle index predicts long-term outcomes of intrahepatic cholangiocarcinoma patients after curative resection.

Hui Li1, Junlong Dai2, Tian Lan2, Hailing Liu2, Jinju Wang2, Bole Cai2, Lin Xu3, Kefei Yuan4, Genshu Wang5, Hong Wu6.   

Abstract

BACKGROUND & AIMS: Sarcopenia is characterized by loss of skeletal muscle mass and associated with poor postoperative outcomes. This study aimed to investigate the prognostic value of preoperative albumin-globulin score (AGS), skeletal muscle index (SMI) as well as their combination in patients with intrahepatic cholangiocarcinoma (ICC) treated with surgical resection.
METHODS: A total of 613 newly diagnosed ICC patients from two centers were retrospectively analyzed (460 in discovery cohort and 153 in validation cohort). The plain computed tomography images were used to measure SMI. The effect of AGS, SMI and CAS grade on clinicopathological characteristics and long-term outcomes of patients with ICC were analyzed.
RESULTS: The SMI was significantly greater in males than in females. Patients with decreased AGS, increased SMI were associated with improved overall survival (OS) and recurrence-free survival (RFS). Stratefied by CAS grade, 68 (14.8%) patients in grade 1 were associated with increased body mass index (BMI) and best postoperative prognosis, whereas 194 (42.1%) patients in grade 3 were linked to worst OS and RFS. The CAS grade showed a promising accuracy in predicting OS and RFS of ICC patients (area under curves [AUCs] were 0.732 and 0.768). Multiple tumors, MVI and elevated CAS grades were identified as independent risk factors for OS and RFS of ICC patients. These results were confirmed by validation cohort.
CONCLUSION: The present study provided compelling evidence that a novel index based on combination of preoperative AGS and SMI was closely related to postoperative long-term outcomes for surgically treated ICC patients. Preoperative evaluation of CAS grade may be useful for risk classification and clinical therapeutic decision-making for ICC patients.
Copyright © 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Albumin-globulin score; Intrahepatic cholangiocarcinoma; Prognostic indicator; Skeletal muscle index; Surgery

Mesh:

Substances:

Year:  2021        PMID: 34134006     DOI: 10.1016/j.clnu.2021.04.038

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  5 in total

1.  Importance of Normalization of Carbohydrate Antigen 19-9 in Patients With Intrahepatic Cholangiocarcinoma.

Authors:  Hui Li; Yuan Feng; Chang Liu; Jiawang Li; Jiaxin Li; Hong Wu; Genshu Wang; Dewei Li
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

2.  Combination of Total Psoas Index and Albumin-Globulin Score for the Prognosis Prediction of Bladder Cancer Patients After Radical Cystectomy: A Population-Based Study.

Authors:  Keyi Wang; Yongzhe Gu; Jinliang Ni; Houliang Zhang; Jinbo Xie; Tianyuan Xu; Jiang Geng; Weipu Mao; Bo Peng
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244

3.  Clinical significance of albumin to globulin ratio among patients with stroke-associated pneumonia.

Authors:  Lingli Chen; Minjie Xu; Qiqi Huang; Yuntao Liu; Wenwei Ren
Journal:  Front Nutr       Date:  2022-08-16

4.  A novel nutritional score based on serum triglyceride and protein levels predicts outcomes of intrahepatic cholangiocarcinoma after curative hepatectomy: A multi-center study of 631 patients.

Authors:  Yunshi Cai; Shuai Xue; Jiaxin Li; Heng Xiao; Tian Lan; Hong Wu
Journal:  Front Nutr       Date:  2022-09-21

5.  Tumor Burden Score Stratifies Prognosis of Patients With Intrahepatic Cholangiocarcinoma After Hepatic Resection: A Retrospective, Multi-Institutional Study.

Authors:  Hui Li; Rongqiang Liu; Haizhou Qiu; Yang Huang; Wenbin Liu; Jiaxin Li; Hong Wu; Genshu Wang; Dewei Li
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.